| Preliminary programme | |
| Arrival/Registration/ Breakfast | |
| 09.30 | Introduction Chris Doherty, Alderley Park |
| Opening Keynote | |
| 09.40 | Challenges and Opportunities Ruth Roberts, ApconiX |
| 10.00 | Enhancing the detection of cardiovascular change: where Maths meets medicine Manasi Nandi, KCL |
| Session 1: Target | |
| 10.45 | Using AI to enhance our understanding of target biology Daniel Jamieson, Biorelate |
| 11.15 | Target Safety Assessment Claire Sadler, ApconiX |
| Short presentations | |
| 11.45 | Metabolite profiling of drug molecules in 3D human liver microtissue incubations. A correlation with cellular toxicity Lloyd King, UCB |
| 11.55 | Managing genotoxicity positive results in discovery – challenges and mitigation Matthew Tate, Gentronix |
| 12.05 | Development of a human keratinocyte-based assay to predict likelihood of skin rash in response to EGFR inhibitors Ambra Bianco, AstraZeneca |
| 12.15 | Imaging applications in toxicologic pathology Juliana Maynard, Medicines Discovery Catapult |
| 12.25 | Lunch, exhibition, tour and poster session |
| Session 2: Chemistry | |
| 13.30 | New Tools for Early Prediction of Hepatotoxicity at GSK Melanie Sakatis, GSK |
| 14.00 | The use of human liver Microtissues in de-risking drug induced liver injury Paul Walker, Cyprotex |
| 14.30 | Discovery Safety – Early impact of chemical design to achieve molecules with the Right Safety Mikael Persson, AstraZeneca |
| Session 3: Patient | |
| 15.00 | Focusing on the patient; recent learning from EGFR TKI clinical development Paul Dickinson, SEDA & Richard Knight, ApconiX |
| Closing Keynote | |
| 15.30 | Biomarkers to improve patient outcomes
Caroline Dive CBE, CRUK |
| 16.15 | Poster Prizes and Prosecco Reception |
| 17.30 | Close |
|
This meeting is organised by:
This meeting is sponsored by:
|
|
